Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
about
Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016.Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology.Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years
P2860
Q38944862-48E0C3BD-4C93-4D56-8E8B-22C4A2659F16Q40056360-5822BF91-3F22-461A-AD03-C0D622F2026FQ40175191-F4292DC4-AA57-4F65-9BC5-2EEF41F2A7F8Q40350783-68A43FFE-3E3A-4AB6-914F-509150AC90F2Q47677580-3CCB7EC9-B305-4717-827A-2FAA584EA070Q49196415-A3A6FB4C-3763-4658-AD0B-D1D9D129752FQ50054283-5CD0B72F-51C0-47E5-A44A-D59E2C2F453DQ52695014-98F5D6DC-1222-408F-9F5B-4AC195A6E958Q55323463-2EC82B11-0663-4F0A-906D-04BFDF14D56DQ58795590-F25221BD-E27A-4D69-8F01-9C9CFEB1090F
P2860
Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacodynamic Evaluation of ...... roducing Klebsiella pneumoniae
@en
Pharmacodynamic Evaluation of ...... oducing Klebsiella pneumoniae.
@nl
type
label
Pharmacodynamic Evaluation of ...... roducing Klebsiella pneumoniae
@en
Pharmacodynamic Evaluation of ...... oducing Klebsiella pneumoniae.
@nl
prefLabel
Pharmacodynamic Evaluation of ...... roducing Klebsiella pneumoniae
@en
Pharmacodynamic Evaluation of ...... oducing Klebsiella pneumoniae.
@nl
P2093
P2860
P356
P1476
Pharmacodynamic Evaluation of ...... roducing Klebsiella pneumoniae
@en
P2093
Ana Cristina Gales
Bruno Buranello Costa
James Albiero
Janio Leal Borges Alves
Josmar Mazucheli
Maria Cristina Bronharo Tognim
Silvana Martins Caparroz-Assef
P2860
P304
P356
10.1128/AAC.03099-15
P407
P50
P577
2016-05-02T00:00:00Z